Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiauranib in relapsed small-cell lung cancer
NCT04830813Phase 3Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of chiauranib in small cell lung cancer (SCLC), sponsored by Akeso, Inc.. Started Mar 2021; status: completed.
02
Drugs
chiauranib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04830813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830813.